ciprofloxacin has been researched along with gatifloxacin in 219 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (4.57) | 18.2507 |
| 2000's | 156 (71.23) | 29.6817 |
| 2010's | 46 (21.00) | 24.3611 |
| 2020's | 7 (3.20) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, MA; Domagala, JM; Gogliotti, RD; Gracheck, SJ; Huband, MD; Sanchez, JP; Sesnie, JA; Shapiro, MA | 1 |
| García-March, FJ; Jaén-Oltra, J; Pérez-Giménez, F; Salabert-Salvador, MT; Tomás-Vert, F | 1 |
| Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Keserü, GM | 1 |
| Almstead, JI; Gray, JL; Hu, XE; Kim, NK; Ledoussal, B; Seibel, WL | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Bradbury, BJ; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Ou, Y; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA | 1 |
| Chen, S; Cui, S; McDermott, PF; Meng, J; Paulsen, I; White, DG; Zhao, S | 1 |
| Bronstein, JC; Domagala, JM; Dunham, SA; Ellsworth, EL; Gage, JW; Gracheck, SJ; Hanna, DL; Huband, MD; Joannides, ET; Liu, JY; Nguyen, DQ; Sanchez, JP; Shapiro, MA; Showalter, HD; Singh, R; Stier, MA; Tran, TP; Watson, BM | 1 |
| Klugman, KP; Levin, BR; McGee, L; Rozen, DE | 1 |
| Hashimoto, K; Hayashi, K; Ikee, Y; Nagao, Y; Nakashima, M; Sano, S; Shiro, M | 1 |
| Barth, AL; Castanheira, M; Gales, AC; Nicoletti, AG; Pereira, AS; Pignatari, AC | 1 |
| Cohen, MA; Ellsworth, E; Gage, JW; Gibson, GW; Gracheck, SJ; Hanna, DL; Huband, MD; Skerlos, LA; Stier, MA; Sulavik, MC; Zurack, M | 1 |
| Jain, M; Jayadev, S; Mishra, B; Patel, PR; Solanki, M; Soni, R; Srivastava, BK; Valani, D | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Clark, KP; Griffith, ME; Hawley, JS; Hospenthal, DR; Johnson, EN; Moon, JE; Murray, CK | 1 |
| Courvalin, P; Galimand, M; Périchon, B | 1 |
| Castanheira, M; Jones, RN; Mendes, RE; Sader, HS; Toleman, MA; Walsh, TR | 1 |
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Adams, DA; Donskey, CJ; Riggs, MM | 1 |
| Morgan-Linnell, SK; Zechiedrich, L | 1 |
| Acosta, CJ; Agtini, M; Albert, MJ; Anh, DD; Arjyal, A; Basnyat, B; Bhattacharya, SK; Bhutta, ZA; Campbell, JI; Canh, DG; Chau, TT; Chinh, NT; Clemens, JD; Diep, TS; Dolecek, C; Dong, B; Dougan, G; Dutta, S; Farrar, J; Galindo, CM; Hien, TT; Honghui, Y; La, TT; Naheed, A; Newton, PN; Nga, TT; Ochiai, RL; Page, AL; Parry, CM; Phetsouvanh, R; Phuong, LT; Rang, NN; Schultsz, C; Tuan, PQ; Van Be Bay, P; Van Minh Hoang, N; Van Vinh Chau, N; Vinh, H; von Seidlein, L; Wain, J | 1 |
| Andres, P; Centrón, D; Galas, M; Guerriero, L; Petroni, A; Quiroga, C; Quiroga, MP; Soler Bistué, AJ; Tokumoto, M; Tolmasky, ME; Vargas, LJ; Zorreguieta, A | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Ednie, L; McGhee, P; Smith, K | 1 |
| China, A; Dinakaran, M; Nagaraja, V; Senthilkumar, P; Sriram, D; Yogeeswari, P | 1 |
| Bitting, C; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Woolhiser, L | 1 |
| Ho, YR; Hung, KH; Janapatla, RP; Wu, CW; Wu, HM; Wu, JJ; Yan, JJ | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bonventre, EJ; Doyle, TB; Du, Q; Duncan, L; Lynch, AS; Morris, TW; Robertson, GT; Roche, ED; Yan, D | 1 |
| Jia, L; Sun, H | 1 |
| Béliveau, C; Labbé, AC; Laverdière, M; Louie, T; Maccannell, D; Pépin, J; Poirier, L; Savoie, M | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 1 |
| Hiramatsu, K; Kikuchi, K; Ohtsuka, M; Ono, Y; Sasaki, T; Shimizu, K; Takahashi, N | 2 |
| Arhin, FF; Caron, L; Delorme, D; Dietrich, E; Fadhil, I; Ferreira, SS; Houghton, TJ; Kang, T; Laquerre, K; Lehoux, D; Liu, J; Moeck, G; Ostiguy, V; Parr, TR; Poirier, H; Rafai Far, A; Sarmiento, I; Tanaka, KS; Viens, F | 1 |
| Arhin, FF; Delorme, D; Dietrich, E; Fadhil, I; Far, AR; Ferreira, SS; Houghton, TJ; Kang, T; Lafontaine, Y; Laquerre, K; Lehoux, D; Liu, J; Moeck, G; Ostiguy, V; Parr, TR; Poirier, H; Sarmiento, I; Tanaka, KS; Viens, F | 1 |
| Becnel Boyd, L; Morgan-Linnell, SK; Steffen, D; Zechiedrich, L | 1 |
| Becnel Boyd, L; Hamill, RJ; Horton, LB; Jimenez, JR; Maynard, MJ; Morgan-Linnell, SK; Steffen, D; Sucgang, R; Versalovic, J; Zechiedrich, L | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Hirakata, Y; Imamura, Y; Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Seki, M; Sugahara, K; Yamamoto, K; Yamamoto, Y; Yanagihara, K | 1 |
| Brunner, LS; Haas, W; Lee, JC; Morris, TW; Pillar, CM; Zurenko, GE | 1 |
| Chhasatia, MR; Gandhi, DS; Patel, MN | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Ekambaram, R; Raghunathan, M; Raghunathan, R; Rao, SS | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Martínez, JL; Sánchez, MB | 1 |
| Anquetin, G; Biot, C; Dive, D; Dubar, F; Khalife, J; Pradines, B | 1 |
| Avdeef, A; Sun, N; Tam, KY; Tsinman, O | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Barber, M; Eberly, LE; Feeney, LA; Miller, GH; Summers, A; Wortmann, G; Zapor, MJ | 1 |
| Sen, S; Sinha, N | 1 |
| Anquetin, G; Aubry, A; Capton, E; Gomez, C; Jarlier, V; Lamouri, A; Pantel, A; Ponien, P; Serradji, N | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Lynch, AS; Ma, Z | 1 |
| Brozovic, A; Dowson, CG; Gazvoda, M; Košmrlj, J; Lloyd, A; Osmak, M; Proud, C; Roper, DI; Vajs, J | 1 |
| Feng, LS; Liu, X; Pan, B; Zhang, GF; Zhang, S | 1 |
| Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ | 1 |
| Liu, ML; Liu, X; Pan, B; Zhang, GF; Zhang, S | 1 |
| Bai, L; Deng, JL; Gao, F; Lv, ZS; Wang, Y; Xu, Z; Zhang, F; Zhao, SJ | 1 |
| Ba, Y; Hou, X; Wang, S; Xu, Z; Yang, H; Zhang, J | 1 |
| Ciura, K; Fallarero, A; Fedorowicz, J; Gilbert-Girard, S; Konopacka, A; Lejnowski, D; Morawska, M; Sączewski, J; Savijoki, K; Skok, Ž; Tomašič, T; Waleron, K | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Dana, S; Dhar, SK; Gurung, SK; Kumar, S; Mondal, N; Mukhopadhyay, P; Valissery, P | 1 |
| Brady, SF; Koirala, B; Peek, J | 1 |
| Bhagwat, S; Bhawsar, S; Deshpande, P; Joshi, S; Patel, M; Yeole, R | 1 |
| Aoyama, H; Fukuda, H; Hirai, K; Hosaka, M; Tomizawa, H; Yasue, T | 1 |
| Chida, K; Hayakawa, H; Iwata, M; Kitazawa, H; Sato, A | 1 |
| Andrews, JM; Boswell, F; Brenwald, NP; Wise, R | 1 |
| Bauernfeind, A | 1 |
| Beach, ML; Doern, GV; Jones, RN; Pfaller, MA | 1 |
| Dubois, J; St-Pierre, C | 1 |
| Appelbaum, PC; Hoellman, DB; Jacobs, MR; Lin, G | 1 |
| Brisse, S; Fluit, AC; Köhrer, K; Martin, N; Milatovic, D; Scheuring, S; Schmitz, FJ; Verhoef, J | 1 |
| Losnedahl, KJ; Pendland, SL; Schriever, CA | 1 |
| Hershberger, E; Rybak, MJ | 1 |
| Firsov, AA; Kononenko, OV; Lubenko, IY; Vostrov, SN; Zinner, SH | 1 |
| Berger, S; Gajjar, DA; Grasela, DM; Kollia, GD; LaCreta, FP; Smith, WB; Stolz, RR; Swingle, M | 1 |
| Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H | 1 |
| Hollauer, K; Kirchbauer, D; Naber, KG; Witte, W | 1 |
| Bonner, D; Conetta, B; Fung-Tomc, J; Huczko, E; Macko, A; Stickle, T; Valera, L | 1 |
| Bonner, DP; Fung-Tomc, J; Gradelski, E; Kolek, B; Minassian, B; Valera, L | 1 |
| Bartlett, MG; Stewart, JT; Vishwanathan, K | 1 |
| Jones, RN; Pfaller, MA | 1 |
| Biedenbach, DJ; Jones, RN; Pfaller, MA | 1 |
| Bonner, DP; Fung-Tomc, J; Gradelski, E; Huczko, E; Minassian, B | 1 |
| Boos, M; Fluit, AC; Hafner, D; Jagusch, H; Mayer, S; Schmitz, FJ; Verhoef, J | 1 |
| Appelbaum, PC; Davies, TA; Dewasse, BE; Jacobs, MR; Nagai, K | 1 |
| Hooper, DC; Ince, D | 1 |
| Firsov, AA; Gilbert, D; Lubenko, IY; Simmons, K; Zinner, SH | 1 |
| Andriole, VT; Bassetti, M; Callan, DA; Dembry, LM; Farrel, PA | 1 |
| Beach, ML; Jones, RN; Pfaller, MA | 1 |
| Frothingham, R | 2 |
| Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E | 1 |
| Kirstein, JM; Mathew, CP; Orchard, D; Richard, GA; Yang, JY | 1 |
| Auerbach, SM; Brown, GL; Cox, CE; Fox, BC; Marbury, TC; Pittman, WG; Yang, JY | 1 |
| Karenchak, LM; Kowalski, RP; Mather, R; Romanowski, EG | 1 |
| Bosso, JA; Enzweiler, KA; Friedrich, LV; Hoban, D; Wagner, D; White, RL | 1 |
| Schaeffer, AJ | 1 |
| Brown-Elliott, BA; Crist, CJ; Mann, L; Wallace, RJ; Wilson, RW | 1 |
| Garey, KW; Jung, R; Neuhauser, MM; Pendland, SL; Prause, JL | 1 |
| Cheong, HJ; Choo, YS; Kang, MW; Kim, WJ; Kim, YS; Lee, KW; Park, YJ; Woo, JH; Yong, DE | 1 |
| Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
| Araake, M; Hara, T; Nishino, T; Shimizu, M; Tabata, M; Watabe, H | 1 |
| Hasegawa, M; Kobayashi, I; Matsuzaki, K; Sato, Y; Shikano, M; Watabe, E; Yoshimori, K | 1 |
| Araake, M; Maebashi, K; Tani, M; Watabe, H | 1 |
| Bello, S; Torres, A | 1 |
| Chiang, SR; Chuang, YC; Ko, WC; Lee, HC; Tang, HJ; Wang, YY | 1 |
| Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T | 1 |
| Doganay, M; Esel, D; Sumerkan, B | 1 |
| Piddock, L; Ricci, V | 1 |
| Dhaliwal, DK; Gordon, YJ; Karenchak, LM; Kowalski, RP; Mah, FS; Ritterband, DC; Romanowski, EG | 1 |
| Ebisu, H; Fukuda, H; Kishii, R; Takei, M | 1 |
| Almaraz, F; Baquero, F; Cantón, R; Jones, RN; Loza, E; Martín, R; Morosini, MI; Pascual, A; Perea, E; Tubau, F | 1 |
| Leggett, J; Saravolatz, LD | 1 |
| Fukuda, Y; Hirakata, Y; Kadota, J; Kohno, S; Miyazaki, Y; Murata, I; Otsu, Y; Tashiro, T; Tomono, K; Tsukamoto, K; Yanagihara, K | 1 |
| Hong, JW; Hu, CQ; Sheng, LS | 1 |
| Choo, CM; Lim, T; Lim, YS; Ngan, CC; Toh, GL | 1 |
| Ankel-Fuchs, D; Boy, D; Kinzig-Schippers, M; Naber, KG; Sörgel, F; Well, M | 1 |
| Ankel-Fuchs, D; Bartnicki, A; Bischoff, W; Hanus, M; Milutinovic, S; Naber, KG; Schönwald, S; van Belle, F; Weitz, P | 1 |
| Acharya, B; Arakawa, S; Gotoh, A; Hinata, N; Kamidono, S; Kawabata, M; Kinoshita, S; Kofuku, T; Okada, H; Shigemura, K; Shirakawa, T | 1 |
| Brooks, TJ; Lever, MS; Sefton, AM; Simpson, AJ; Steward, J | 1 |
| Guo, HY; Liu, ML; Qi, JJ; Sun, LY | 1 |
| Allin, DM; Ankel-Fuchs, D; Clarysse, L; Haworth, DA; Hopkins, G; James, IG; Naber, KG; Raini, C; Schneider, H; Wall, A; Weitz, P | 1 |
| Fukuda, Y; Hirakata, Y; Kadota, J; Kohno, S; Miyazaki, Y; Murata, I; Tashiro, T; Tomono, K; Tsukamoto, K; Yanagihara, K | 1 |
| Dick, JD; Hose, S; Hyon, JY; Joo, MJ; O'Brien, TP; Sinha, D | 1 |
| Beedham, RJ; Brooks, TJ; Lever, MS; Russell, P; Stagg, AJ; Steward, J; Taylor, RR | 1 |
| Burgess, DS; Frei, CR; Moczygemba, LR | 1 |
| Evangelista, AT; Jones, ME; Karlowsky, JA; Sahm, DF; Thornsberry, C; Yee, YC | 1 |
| Carrier, M; Jensen, H; Short, B; Zerouala, C | 1 |
| Brooks, TJ; Lever, MS; Nelson, M; Piercy, T; Simpson, AJ; Steward, J | 1 |
| Bloom, A; Donnenfeld, ED; Nedrud, C; Perry, HD; Snyder, RW; Solomon, R; Stein, J | 1 |
| Miller, J | 1 |
| Paramasivan, CN; Rahman, F; Sulochana, S | 1 |
| Ashcraft, DS; Pankey, GA | 1 |
| Graff, JM; Kesler-Diaz, A; McDonnell, PJ; Osann, KE; Reiser, BJ; Sarayba, MA; Shamie, N; Sweet, PM; Taban, M | 1 |
| Abelson, MB; Shapiro, A; Torkildsen, G; Wagner, RS | 1 |
| Kenton, I; McKinnon, PS; Mohr, JF; Okhuysen, PC; Peymann, PJ; Septimus, E | 1 |
| Brooks, TJ; Lever, MS; Piercy, T; Steward, J | 1 |
| Horii, T; Monji, A; Nagura, O; Uemura, K | 1 |
| Al-Dgither, S; Alvi, SN; Hammami, MM | 1 |
| Garrison, MW | 1 |
| Donnenfeld, ED; Donnenfeld, RS; Jensen, HG; Perry, HD; Snyder, RW; Solomon, R; Stein, J; Wittpenn, JR | 1 |
| Fukuda, H; Hayashi, K; Kadowaki, SE; Takei, M | 1 |
| Jesudasan, CA; Kalavathy, CM; Kaliamurthy, J; Parmar, P; Prasanth, DA; Salman, A; Thomas, PA | 1 |
| Anguita-Alonso, P; Jacofsky, DJ; Osmon, DR; Patel, R; Piper, KE; Rouse, MS | 1 |
| Brooks, TJ; Lever, MS; Piercy, T; Simpson, AJ; Steward, J | 1 |
| Arpin, C; Ba, BB; Chausse, A; Quentin, C; Saux, MC; Vidaillac, C | 1 |
| Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM | 1 |
| Bosso, JA; Mauldin, PD | 1 |
| Black, JA; Moland, ES; Thomson, KS; Wickman, PA | 1 |
| Eiland, E; Hassoun, A | 1 |
| Aydemir, S; Cilli, F; Tunger, A | 1 |
| Garg, RK; Marak, RS; Ray, P; Sharma, J | 1 |
| Amarnath, SK; Joshi, S | 1 |
| Black, JA; Hanson, ND; Smith Moland, E; Thomson, KS; Wickman, PA | 1 |
| Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG | 1 |
| Fiscella, RG; Jensen, MK | 1 |
| Rodríguez, JC; Royo, G; Ruiz, M; Sirvent, E | 1 |
| Harish, BN; Menezes, GA; Parija, SC; Sarangapani, K | 1 |
| D'Azevedo, PA; Francisco, W; Oliveira, AD | 1 |
| Miyata, K; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Amyes, SG; Dobay, O; Ghidán, A; Matuz, M; Nagy, K; Rozgonyi, F | 1 |
| Catero, M | 1 |
| Blondeau, JM; Borsos, S; Hesje, CK | 1 |
| Blondeau, JM; Hedlin, P | 1 |
| Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Yates, KA | 1 |
| Asari, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Osaka, Y; Yasuda, S | 1 |
| Bezwada, P; Clark, LA; Schneider, S | 1 |
| Arias, CA; Cárdenas, AM; Castañeda, E; Díaz, L; Díaz, PL; Hidalgo, M; Reyes, J; Rincón, S; Vanegas, N | 1 |
| Fiscella, RG; Jensen, MK; Mooney, B; Moshirfar, M | 1 |
| Asbell, PA; Epstein, SP; Sosa, AB | 1 |
| Bai, XQ; Deng, SJ; Li, L; Li, R; Liang, QF; Luo, SY; Sun, XG; Wang, ZQ | 1 |
| Horstkotte, MA; Knobloch, JK; Mack, D; Rohde, H; Von Osten, H | 1 |
| Bosgelmez-Tinaz, G; Coskun-Ari, FF | 1 |
| Qi, HM; Wei, MJ; Zhang, L; Zhao, CY | 1 |
| Choi, JS; Joo, CK; Kim, KA; Lim, JA; Park, SH | 1 |
| Holland, EJ; Lane, SS; Lindstrom, RL | 1 |
| McCulley, JP | 1 |
| Alam, MR; Garg, P; Gopinathan, U; Krishnaiah, S; Reddy, AK; Sharma, S | 1 |
| Conway, J; Hutson, P; Leiferman, EM; Noonan, KJ; Sansone, JM; Wilsman, NJ | 1 |
| Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Chen, WL; Hu, FR; Tsai, TH | 1 |
| Anupama, M; Murthy, PB; Seiler, JP | 1 |
| Araújo, DP; de Almeida, MV; de Carvalho, GS; de Souza, MV; Saraiva, MF; Tran Huu Dau, ME | 1 |
| Chang, CL; Choi, GE; Kang, JE; Kim, JM; Kim, KH; Lee, EY; Tateda, K; Yamaguchi, K | 1 |
| Banaszkiewicz, A; Młynarczyk, G; Obuch-Woszczatyński, P; Pituch, H; Radzikowski, A; Wultańska, D | 1 |
| Acharya, NR; Cevallos, V; Fintelmann, RE; Gaynor, BD; Hoskins, EN; Keenan, JD; Lietman, TM | 1 |
| Ambrose, PG; Bhavnani, SM; Caws, M; Chau, TT; Dung, NT; Farrar, J; Hammel, JP; Hien, TT; Kulawy, R; Mai, PP; Reynolds, DK; Thwaites, GE; Török, ME; Van Wart, SA | 1 |
| Green, K; Low, DE; McGeer, A; Melano, R; Patel, SN; Pillai, DR; Tyrrell, GJ | 1 |
| Anh, ND; Anh, VT; Baker, S; Bay, PV; Campbell, JI; Chau, NV; Chinh, MT; Day, JN; Diep, TS; Dolecek, C; Duy, PT; Farrar, JJ; Hoang, NV; Lan, NP; Loan, HT; Minh, PV; Mong, BL; Nga, TV; Nhu, NT; Phuong, le T; Tham, NT; Thao, NT; Thuy, CT; Vinh, H; Wolbers, M | 1 |
| Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA | 1 |
| Chavda, K; Drlica, K; Hussain, S; Kerns, RJ; Kreiswirth, BN; Kurepina, N; Malik, M; Shah, N; Zhao, X | 1 |
| Liu, M; Xia, Q; Yang, Y | 1 |
| Kim, JN; Park, M; Rafii, F; Sutherland, JB | 1 |
| Bian, A; Blackman, A; Eden, S; Maruri, F; Mitchel, E; Shintani, AK; Sterling, TR; van der Heijden, YF; Warkentin, JV | 1 |
| Kalavathy, CM; Kaliamurthy, J; Nelson Jesudasan, CA; Parmar, P; Thomas, PA | 1 |
| Ai, NT; Baker, S; Campbell, JI; Dong, N; Dougan, G; Dung, TT; Farrar, JJ; Hien, TT; Hoang, NV; Holt, KE; Kim, DW; Lien, NT; Minh, PV; Nga, TT; Nhu, NT; Parkhill, J; Parry, CM; Phu, BD; Phuc, HL; Thanh, DP; Thieu Nga, TV; Thompson, C; Thomson, NR; Thuy, CT; Tien, NM; Tuyet, PT; Vinh, H; Vinh, NT; Vinh, PV; Vu Tra, MP | 1 |
| Ghaly, H; Jörns, A; Rustenbeck, I | 1 |
| Betlejewska-Kielak, K; Biernacka, J; Grudzień, M; Kłosińska-Szmurło, E; Mazurek, AP; Pluciński, FA | 1 |
| Wu, L; Wu, X | 1 |
| Baker-Austin, C; Fletcher, DE; McArthur, JV; Tuckfield, RC | 1 |
| Arjyal, A; Baker, S; Basnyat, B; Dolecek, C; Dongol, S; Dougan, G; Gajurel, D; Ha Thanh, T; Ho Thi, N; Holt, KE; Karkey, A; Parry, CM; Pham Thanh, D; Pickard, D; Pradhan, A; Rabaa, MA; Shrestha, SK; Thompson, CN; Thwaites, GE; Tran Vu Thieu, N; Voong Vinh, P; Wolbers, M; Wong, V | 1 |
| Hsu, MC; Leunk, R; Makin, K; Roychoudhury, S; Twinem, T | 1 |
| Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C | 1 |
| Abdelbacki, AMM; El-Gebaly, RH; Fadel, MA; Mohamed, SA | 1 |
| Balaji, V; Bandyopadhyay, R; Jasmine, S; Rupali, P; Sathyendra, S; Yadav, B | 1 |
| Lan, R; Shen, R; Xia, Z; Yu, R; Yu, Y; Yuan, Z | 1 |
| Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T | 1 |
| Ebrahimzadeh, F; Gholami, S; Jafari-Sales, A; Rostami, A; Zadeh, FA | 1 |
| Bykov, K; Fischer, MA; Gagne, JJ; Kattinakere-Sreedhara, S; Wang, J | 1 |
| Agrawal, D; Chatterjee, S; Gangwe, AB; Gomase, SN; Mishra, M; Parchand, SM | 1 |
9 review(s) available for ciprofloxacin and gatifloxacin
| Article | Year |
|---|---|
4-Quinolone derivatives and their activities against Gram positive pathogens.
Topics: 4-Quinolones; Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship | 2018 |
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis | 2018 |
Ciprofloxacin derivatives and their antibacterial activities.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Gram-Negative Bacteria; Gram-Positive Bacteria; Molecular Structure; Structure-Activity Relationship | 2018 |
Fluoroquinolone-isatin hybrids and their biological activities.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antitubercular Agents; Antiviral Agents; Fluoroquinolones; Humans; Isatin; Structure-Activity Relationship | 2019 |
Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
Topics: Anti-Bacterial Agents; Bacterial Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Nitroimidazoles | 2019 |
Quinolone antibiotics.
Topics: | 2019 |
The expanding role of fluoroquinolones.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Norfloxacin; Ofloxacin; Quinolones; Urinary Tract Infections | 2002 |
Dysglycemia and fluoroquinolones: are you putting patients at risk?
Topics: Adolescent; Adult; Aza Compounds; Bacterial Infections; Blood Glucose; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Evidence-Based Medicine; Family Practice; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Incidence; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Randomized Controlled Trials as Topic; Risk Assessment; United States; United States Food and Drug Administration | 2007 |
Globally Vibrio cholera antibiotics resistance to RNA and DNA effective antibiotics: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Cephalothin; Cholera; Cholera Toxin; Ciprofloxacin; Drug Resistance, Bacterial; Furazolidone; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Nalidixic Acid; Nitrofurantoin; Norfloxacin; Novobiocin; Rifampin; Vibrio cholerae; Virulence Factors | 2022 |
11 trial(s) available for ciprofloxacin and gatifloxacin
| Article | Year |
|---|---|
Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.
Topics: Adult; Anti-Infective Agents; Blood Glucose; Ciprofloxacin; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Female; Fluoroquinolones; Gatifloxacin; Glucose Tolerance Test; Humans; Insulin; Islets of Langerhans; Male; Middle Aged | 2000 |
Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Middle Aged; Recurrence; Treatment Outcome; Urinary Tract Infections | 2002 |
A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Pyelonephritis; Urinary Tract Infections | 2002 |
Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Cross-Over Studies; Female; Fluoroquinolones; Gatifloxacin; Humans; Kinetics; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Reference Values | 2004 |
Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections.
Topics: Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Pyelonephritis; Treatment Outcome; Urinary Tract Infections | 2004 |
Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections; Urine | 2004 |
Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor.
Topics: Aged; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cataract Extraction; Chromatography, High Pressure Liquid; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Quinolines | 2005 |
Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Child; Ciprofloxacin; Corneal Ulcer; Double-Blind Method; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Microbial Sensitivity Tests; Microbiological Techniques; Middle Aged; Ophthalmic Solutions; Prospective Studies | 2006 |
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intramuscular; Isoniazid; Levofloxacin; Male; Middle Aged; Multivariate Analysis; Ofloxacin; Pyrazinamide; Rifampin; Streptomycin; Tuberculosis, Meningeal; Young Adult | 2011 |
A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children.
Topics: Anti-Bacterial Agents; Child, Preschool; Ciprofloxacin; Dysentery, Bacillary; Feces; Female; Fluoroquinolones; Gatifloxacin; Hospitals; Humans; Hyperglycemia; Hypoglycemia; Infant; Male; Proportional Hazards Models; Shigella; Treatment Outcome; Vietnam | 2011 |
A novel ciprofloxacin-resistant subclade of H58 Salmonella Typhi is associated with fluoroquinolone treatment failure.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Ceftriaxone; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Genotype; Humans; Nepal; Salmonella typhi; Sequence Analysis, DNA; Treatment Failure; Typhoid Fever | 2016 |
199 other study(ies) available for ciprofloxacin and gatifloxacin
| Article | Year |
|---|---|
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
Topics: Animals; Anti-Bacterial Agents; Bacteria; CHO Cells; Cricetinae; Dermatitis, Phototoxic; Drug Design; Female; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 1995 |
Artificial neural network applied to prediction of fluorquinolone antibacterial activity by topological methods.
Topics: Algorithms; Anti-Infective Agents; Fluoroquinolones; Microbial Sensitivity Tests; Neural Networks, Computer; Structure-Activity Relationship | 2000 |
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens.
Topics: Anti-Bacterial Agents; Bacteria; DNA Gyrase; DNA, Superhelical; Drug Resistance, Bacterial; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Models, Molecular; Molecular Conformation; Piperidines; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
Topics: Anti-Bacterial Agents; Azo Compounds; Cell Line; Escherichia coli; Humans; Hydrocarbons, Aromatic; Microbial Sensitivity Tests; Molecular Structure; Quinolines; Staphylococcus aureus; Sulfhydryl Compounds | 2006 |
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
Topics: Animals; Anti-Infective Agents; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Gene Targeting; Genes, Bacterial; Mutation; Salmonella Infections, Animal; Salmonella typhimurium | 2007 |
3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.
Topics: Anti-Bacterial Agents; Bacteria; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; Methicillin Resistance; Microbial Sensitivity Tests; Quinazolinones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2006 |
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
Topics: DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Pneumococcal Infections; Streptococcus pneumoniae; Transformation, Bacterial | 2007 |
Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane.
Topics: Anti-Bacterial Agents; Aza Compounds; Bridged Bicyclo Compounds; Crystallography, X-Ray; Indicators and Reagents; Magnetic Resonance Spectroscopy; Methicillin Resistance; Microbial Sensitivity Tests; Models, Molecular; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Structure-Activity Relationship | 2007 |
First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Conjugation, Genetic; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Integrons; Latin America; Molecular Sequence Data; Plasmids | 2007 |
In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Microbial Sensitivity Tests; Pyrrolidines; Quinazolinones; Topoisomerase II Inhibitors | 2007 |
Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chemistry, Pharmaceutical; Ciprofloxacin; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Models, Chemical; Molecular Conformation; Pyridines; Quinolones | 2007 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Doxycycline; Female; Fluoroquinolones; Gatifloxacin; Injections, Intraperitoneal; Leptospira interrogans; Leptospirosis; Levofloxacin; Mesocricetus; Ofloxacin; Serotyping; Survival Analysis | 2007 |
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
Topics: Amino Acid Motifs; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Conjugation, Genetic; Conserved Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Genes, rRNA; Methylation; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Norfloxacin; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2007 |
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
Topics: Acinetobacter; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Brazil; Codon, Terminator; Cross Infection; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Genes, Bacterial; Hospitals; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Open Reading Frames; Plasmids; Pseudomonas putida; Transcription, Genetic | 2007 |
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Topics: Anaerobiosis; Animals; Anti-Infective Agents; Bacterial Toxins; Cecum; Clostridioides difficile; Disease Models, Animal; Disease Outbreaks; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests | 2007 |
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
Topics: DNA Topoisomerases; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Mutation | 2007 |
Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
Topics: Anti-Bacterial Agents; Asia; Bangladesh; China; DNA Gyrase; DNA Mutational Analysis; DNA Topoisomerase IV; Drug Resistance, Microbial; Fluoroquinolones; Humans; India; Indonesia; Laos; Microbial Sensitivity Tests; Mutation; Nepal; Pakistan; Salmonella typhi; Vietnam | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross Infection; DNA Transposable Elements; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid | 2007 |
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2008 |
Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Drug Resistance, Multiple, Bacterial; Female; Light; Mice; Microbial Sensitivity Tests; Mycobacterium smegmatis; Mycobacterium tuberculosis; Naphthyridines; Structure-Activity Relationship; Topoisomerase II Inhibitors; Vero Cells | 2007 |
Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
Topics: Animals; Antitubercular Agents; Biological Availability; Interferon-gamma; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridones; Quinolones; Treatment Outcome; Tuberculosis, Pulmonary | 2008 |
Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
Topics: Bacterial Proteins; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Streptococcus agalactiae; Taiwan | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; DNA Topoisomerase IV; DNA-Directed RNA Polymerases; DNA, Bacterial; Drug Resistance, Bacterial; Enzyme Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Mutation; Quinolones; Rifamycins; RNA, Bacterial; Staphylococcus aureus; Topoisomerase II Inhibitors | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.
Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Community-Acquired Infections; Cross Infection; Disease Outbreaks; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Female; Hospitalization; Humans; Incidence; Male; Middle Aged; Prognosis; Quebec; Ribotyping; Risk Factors | 2008 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids | 2008 |
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
Topics: Alleles; Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; Chromosomes, Bacterial; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Gram-Negative Bacterial Infections; Humans; Molecular Sequence Data; Sequence Homology, Amino Acid; Stenotrophomonas maltophilia | 2008 |
Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.
Topics: Animals; Disease Models, Animal; Esters; Female; Fluoroquinolones; Humans; Molecular Structure; Organophosphonates; Osteomyelitis; Prodrugs; Rats | 2008 |
Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis.
Topics: Amines; Animals; Cell Line; Diphosphonates; Female; Fluoroquinolones; Molecular Structure; Osteomyelitis; Prodrugs; Rats; Structure-Activity Relationship | 2008 |
Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Norfloxacin; Ofloxacin | 2009 |
Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
Topics: Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; United States | 2009 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
Emergence of quinolone-resistant Bordetella pertussis in Japan.
Topics: Anti-Bacterial Agents; Bordetella pertussis; Child; DNA Gyrase; Fluoroquinolones; Humans; Japan; Microbial Sensitivity Tests; Mutation; Nalidixic Acid; Quinolones | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2009 |
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Topics: Anti-Bacterial Agents; Azepines; Bacteria, Anaerobic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 2009 |
Interaction of drug based binuclear mixed-ligand complexes with DNA.
Topics: Anti-Bacterial Agents; Bacteria; Binding Sites; Ciprofloxacin; Cobalt; DNA, Bacterial; Ligands; Magnetic Resonance Spectroscopy; Magnetics; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Structure; Oxidation-Reduction; Spectrophotometry, Infrared; Structure-Activity Relationship; Temperature; Viscosity | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2009 |
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Quinolines | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Microbial Sensitivity Tests; Mutation; Plasmids; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Stenotrophomonas maltophilia | 2010 |
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
Topics: Aminoquinolines; Antimalarials; Ciprofloxacin; Ferrous Compounds; Metallocenes; Plasmodium falciparum; Prodrugs | 2009 |
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Topics: Caco-2 Cells; Cell Membrane Permeability; Humans; Hydrogen-Ion Concentration; Membranes, Artificial; Molecular Structure; Pharmaceutical Preparations | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
Topics: Acinetobacter baumannii; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Dibekacin; Hospitals, Military; Humans; Microbial Sensitivity Tests; Warfare | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; DNA Cleavage; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium leprae; Mycobacterium tuberculosis; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2013 |
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Rifamycins; Staphylococcus aureus; Structure-Activity Relationship | 2016 |
Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
Topics: Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mycobacterium smegmatis; Triazenes | 2017 |
Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; HEK293 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Quaternary Ammonium Compounds; Quinolones; Structure-Activity Relationship | 2019 |
Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity.
Topics: | 2020 |
Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; HEK293 Cells; Humans; Microbial Sensitivity Tests; Rifamycins; Staphylococcus aureus | 2022 |
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Piperidines; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus; Streptococcus pneumoniae; Structure-Activity Relationship | 2022 |
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; DNA Topoisomerases, Type II; Drug Evaluation, Preclinical; Fluoroquinolones; Gatifloxacin; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Piperazines; Quinolones; Tissue Distribution | 1992 |
Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aeruginosa in a rat model.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Gatifloxacin; Immunoglobulin A; Immunoglobulin G; Male; Piperazines; Pseudomonas Infections; Quinolones; Rats; Rats, Sprague-Dawley; Tracheal Diseases | 1997 |
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteroides fragilis; Chlamydia; Ciprofloxacin; Clarithromycin; Doxycycline; Enterobacter; Erythromycin; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Haemophilus influenzae; Microbial Sensitivity Tests; Naphthyridines; Piperazines; Pseudomonas aeruginosa; Quinolones; Streptococcus pneumoniae | 1997 |
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus | 1997 |
Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteriological Techniques; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Naphthyridines; North America; Quinolones; South America | 1998 |
In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Ciprofloxacin; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Gatifloxacin; Legionella; Microbial Sensitivity Tests; Rifampin | 1999 |
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Topics: Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterat
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Enterobacter cloacae; Fluoroquinolones; Gatifloxacin; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 1999 |
In-vitro activity of gatifloxacin, a novel fluoroquinolone, compared with that of ciprofloxacin against Legionella spp.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Humans; Legionella; Microbial Sensitivity Tests | 1999 |
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Blood Coagulation; Ciprofloxacin; Fibrin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae | 2000 |
Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.
Topics: Anti-Infective Agents; Area Under Curve; Bacteria; Ciprofloxacin; Computer Simulation; Escherichia coli; Fluoroquinolones; Gatifloxacin; Half-Life; Humans; Klebsiella pneumoniae; Models, Biological; Staphylococcus aureus | 2000 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2000 |
In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Klebsiella; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Urinary Tract Infections | 2000 |
Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998.
Topics: Anti-Infective Agents; Ciprofloxacin; Clinical Trials as Topic; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus pneumoniae | 2000 |
Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Antagonism; Drug Combinations; Drug Interactions; Drug Synergism; Enterococcus faecalis; Escherichia coli; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Streptococcus pneumoniae | 2001 |
Determination of gatifloxacin in human plasma by liquid chromatography/electrospray tandem mass spectrometry.
Topics: Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Time Factors | 2001 |
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
Topics: Anti-Infective Agents; Ciprofloxacin; Databases, Factual; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Gram-Positive Cocci; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Predictive Value of Tests; Pseudomonas aeruginosa | 2001 |
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States | 2001 |
Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Mutation; Neisseria gonorrhoeae; Ofloxacin; Staphylococcus aureus; Streptococcus pneumoniae | 2001 |
Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Streptococcus pneumoniae | 2001 |
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Quinolines; Selection, Genetic; Serotyping; Streptococcus pneumoniae | 2001 |
Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gene Frequency; Genes, Bacterial; Genetic Linkage; Genotype; Microbial Sensitivity Tests; Mutation; Phenotype; Staphylococcus aureus | 2001 |
The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Models, Biological; Streptococcus pneumoniae | 2001 |
Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Ciprofloxacin; Enterococcus; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Staphylococcus; Streptococcus | 2001 |
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Resistance, Bacterial; Europe; Fluoroquinolones; Gatifloxacin; Humans; Lactams; Latin America; Levofloxacin; Microbial Sensitivity Tests; North America; Ofloxacin; Population Surveillance; Pseudomonas aeruginosa; Pseudomonas Infections; Regional Medical Programs; Urinary Tract Infections | 2001 |
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Electrocardiography; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies; Torsades de Pointes | 2001 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins | 2001 |
Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2002 |
Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ceftriaxone; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae; United States | 2002 |
Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium chelonae; Mycobacterium fortuitum | 2002 |
Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration.
Topics: Anti-Infective Agents; Blood Bactericidal Activity; Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Sensitivity and Specificity | 2002 |
In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Haemophilus influenzae; Korea; Levofloxacin; Microbial Sensitivity Tests; Moraxella; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2002 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
[In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Time Factors | 2002 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprofloxacin; Dosage Forms; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Macrolides; Ofloxacin; Otorhinolaryngologic Diseases; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae; Time Factors; Urinary Tract Infections | 2002 |
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Topoisomerase II Inhibitors | 2002 |
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Multivariate Analysis; Mutation; Ofloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Pneumonia, Pneumococcal; Quinolines; Recurrence; Risk Factors; Streptococcus pneumoniae | 2003 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2003 |
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratitis; Keratomileusis, Laser In Situ; Levofloxacin; Ofloxacin; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Surgical Flaps | 2003 |
Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillin G; Penicillins; Turkey | 2003 |
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Corneal Ulcer; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
Topics: Administration, Oral; Area Under Curve; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Theoretical; Ofloxacin; Streptococcus pneumoniae | 2003 |
[Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
Topics: Anti-Infective Agents; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Species Specificity; Staphylococcus aureus; Streptococcus pneumoniae | 2003 |
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2003 |
In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Lung; Male; Mice; Mice, Inbred CBA; Microbial Sensitivity Tests; Penicillin Resistance; Pneumonia, Pneumococcal; Quinolones; Survival Analysis | 2003 |
[Analysis of the response factors of different quinolones detected by evaporative light-scattering detector].
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Light; Linear Models; Ofloxacin; Quinolones | 2003 |
Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clindamycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma hominis; Quinolines; Sampling Studies; Sensitivity and Specificity; Singapore; Tetracycline | 2004 |
Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gonorrhea; Humans; Japan; Levofloxacin; Male; Microbial Sensitivity Tests; Mutation; Neisseria gonorrhoeae; Ofloxacin | 2004 |
Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones.
Topics: Animals; Anthrax; Anti-Infective Agents; Aza Compounds; Bacillus anthracis; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Survival Analysis | 2004 |
[Synthesis and antibacterial activity of 7-(7-aminomethyl-5-azaspiro [2,4] hept-5-yl)-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid and its analogues].
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Male; Mice; Mice, Inbred ICR; Molecular Conformation; Molecular Structure; Quinolines; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae | 2004 |
Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Evaluation, Preclinical; Fluoroquinolones; Gatifloxacin; Levofloxacin; Lung; Mice; Mice, Inbred CBA; Ofloxacin; Penicillin Resistance; Pneumonia, Pneumococcal; Survival Rate | 2004 |
Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis.
Topics: Administration, Topical; Amikacin; Animals; Anti-Bacterial Agents; Ciprofloxacin; Clarithromycin; Cornea; Corneal Ulcer; Disease Models, Animal; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Male; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ophthalmic Solutions; Rabbits | 2004 |
Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Plague; Yersinia pestis | 2004 |
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Klebsiella pneumoniae; Lactams; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Ofloxacin; Thienamycins | 2004 |
Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies.
Topics: beta-Lactams; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Gentamicins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2005 |
Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Ophthalmic Solutions; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Safety; Treatment Outcome; Wound Healing | 2005 |
Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Dexamethasone; Drug Administration Schedule; Female; Fluoroquinolones; Gatifloxacin; Glucocorticoids; Melioidosis; Mice; Mice, Inbred BALB C; Moxifloxacin; Quinolines | 2005 |
Acinetobacter as a causative agent in preseptal cellulitis.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Anti-Infective Agents; Cellulitis; Ciprofloxacin; Drug Therapy, Combination; Eye Infections, Bacterial; Eyelid Diseases; Female; Fluoroquinolones; Gatifloxacin; Humans | 2005 |
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Topics: Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2005 |
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Transplantation; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratitis; Levofloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ofloxacin; Rabbits | 2005 |
Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2005 |
A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Blood Glucose; Ceftriaxone; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Male; Middle Aged; Ofloxacin; Product Surveillance, Postmarketing; Retrospective Studies | 2005 |
Glucose homeostasis abnormalities associated with use of gatifloxacin.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Glucose; Homeostasis; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Dexamethasone; Disease Models, Animal; Female; Fluoroquinolones; Francisella tularensis; Gatifloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Quinolines; Survival Analysis; Tularemia | 2005 |
Rapid detection of fluoroquinolone resistance by isothermal chimeric primer-initiated amplification of nucleic acids from clinical isolates of Neisseria gonorrhoeae.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Gyrase; DNA Primers; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Nucleic Acid Amplification Techniques; Point Mutation; Time Factors | 2006 |
Development and validation of an HPLC method for the determination of gatifloxacin stability in human plasma.
Topics: Acetonitriles; Calibration; Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Stability; Fluoroquinolones; Gatifloxacin; Humans; Models, Chemical; Phosphoric Acids; Quality Control; Reproducibility of Results; Spectrophotometry; Time Factors | 2006 |
Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; DNA, Bacterial; Evaluation Studies as Topic; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa | 2006 |
A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cornea; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Keratitis; Keratomileusis, Laser In Situ; Ophthalmic Solutions; Pneumococcal Infections; Rabbits; Streptococcus pneumoniae; Surgical Wound Infection; Treatment Outcome | 2006 |
Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Lung; Mice; Mice, Inbred BALB C; Ofloxacin; Orthomyxoviridae Infections; Pneumonia, Pneumococcal | 2006 |
Comparative study of antimicrobial release kinetics from polymethylmethacrylate.
Topics: Acetamides; Anti-Bacterial Agents; Area Under Curve; Cefazolin; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Ofloxacin; Oxazolidinones; Polymethyl Methacrylate; Rifampin | 2006 |
Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Tularemia | 2006 |
Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Computer Simulation; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Half-Life; In Vitro Techniques; Microbial Sensitivity Tests; Mutation; Reference Standards; Staphylococcus aureus | 2006 |
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Escherichia coli; Fluoroquinolones; Formularies as Topic; Gatifloxacin; Gram-Negative Bacteria; Humans; Levofloxacin; Methicillin; Methicillin Resistance; Ofloxacin; Pseudomonas aeruginosa; Regression Analysis; Retrospective Studies; Staphylococcus aureus | 2006 |
In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Enterococcus; Fluoroquinolones; Gatifloxacin; Gram-Positive Cocci; In Vitro Techniques; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pyrrolidines; Quinolines; Quinolones; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes | 2006 |
Effectiveness of flouroquinolone therapy for gram-negative infections within the intensive care unit setting.
Topics: Acinetobacter; Alabama; Ciprofloxacin; Drug Resistance, Bacterial; Enterobacter cloacae; Escherichia coli; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, Community; Humans; Intensive Care Units; Klebsiella oxytoca; Microbial Sensitivity Tests; Ofloxacin; Proteus mirabilis; Pseudomonas aeruginosa; Retrospective Studies | 2006 |
In vitro activity of fluoroquinolones against common respiratory pathogens.
Topics: Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Predictive efficacy of nalidixic acid resistance as a marker of fluoroquinolone resistance in Salmonella enterica var Typhi.
Topics: Biomarkers; Cefotaxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Salmonella typhi | 2006 |
Fluoroquinolone resistance in Salmonella typhi and S. paratyphi A in Bangalore, India.
Topics: Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Salmonella paratyphi A; Salmonella typhi | 2007 |
In vitro development of resistance to DX-619 and other quinolones in enterococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Polymerase Chain Reaction; Pyrrolidines; Quinolines; Quinolones; Sequence Analysis, DNA | 2006 |
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genotype; Humans; Infant; Infant, Newborn; Levofloxacin; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Serotyping; Streptococcus pneumoniae | 2007 |
Evaluation of the penetration of fluoroquinolones in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2006 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutagenicity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
Fluoroquinolone resistance among Salmonella enterica serovar Paratyphi A in Pondicherry.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Ofloxacin; Salmonella paratyphi A | 2006 |
In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Brazil; Ciprofloxacin; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Incidence; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2007 |
Antacid interaction with new quinolones: dose regimen recommendations based on pharmacokinetic modeling of clinical data for ciprofloxacin, gatifloxacin and norfloxacin and metal cations.
Topics: Administration, Oral; Aluminum Hydroxide; Antacids; Anti-Infective Agents; Biological Availability; Cations; Ciprofloxacin; Drug Administration Schedule; Drug Combinations; Drug Interactions; Fluoroquinolones; Gatifloxacin; Humans; Intestinal Absorption; Magnesium Hydroxide; Models, Biological; Norfloxacin; Reference Values; Sucralfate | 2007 |
The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Hungary; Microbial Sensitivity Tests; Moxifloxacin; Mutation, Missense; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2006 |
Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Cells, Cultured; Ciprofloxacin; Drug Combinations; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Preservatives, Pharmaceutical; Quinolines; Staphylococcus aureus | 2007 |
Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
Topics: Anti-Infective Agents; Antimutagenic Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Eye; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Osmolar Concentration; Quinolines | 2007 |
Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Serratia Infections; Serratia marcescens; Tobramycin | 2007 |
The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo.
Topics: Biological Transport; Carnitine; Cell Line, Tumor; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Ofloxacin; Organic Cation Transport Proteins; Piperazines; Placenta; Sodium; Solute Carrier Family 22 Member 5 | 2008 |
Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells.
Topics: Anti-Bacterial Agents; Aza Compounds; Biological Assay; Ciprofloxacin; Cornea; Corneal Stroma; Endothelial Cells; Endothelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
[Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colombia; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Enterococcus; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2008 |
Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Cross-Sectional Studies; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines; Retrospective Studies | 2008 |
Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Cell Survival; Ciprofloxacin; Conjunctiva; Drug Evaluation, Preclinical; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tetrazolium Salts; Thiazoles | 2008 |
[Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Eye; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 2008 |
Biofilm formation is not necessary for development of quinolone-resistant "persister" cells in an attached Staphylococcus epidermidis population.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Adhesion; Biofilms; Ciprofloxacin; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Prosthesis-Related Infections; Quinolines; Quinolones; Staphylococcal Infections; Staphylococcus epidermidis | 2008 |
grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Electrophoresis, Agar Gel; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Gatifloxacin; Gene Expression Regulation, Bacterial; Methicillin Resistance; Mutation; Polymerase Chain Reaction; Quinolones; Staphylococcus aureus; Trans-Activators | 2008 |
Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes.
Topics: Animals; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Ciprofloxacin; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Fluoroquinolones; Gatifloxacin; Humans; Isoenzymes; Levofloxacin; Microsomes, Liver; Molecular Structure; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results | 2008 |
The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacteria, Aerobic; Ciprofloxacin; Conjunctiva; Eye; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines | 2009 |
Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Humans; India; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Retrospective Studies; Staphylococcus; Streptococcus | 2010 |
The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model.
Topics: Animals; Anti-Bacterial Agents; Cartilage, Articular; Child; Chromatography, High Pressure Liquid; Ciprofloxacin; Dose-Response Relationship, Drug; Fluorescent Dyes; Fluoroquinolones; Gatifloxacin; Growth Plate; Humans; Male; Models, Animal; Sheep; Tibia | 2009 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Survival; Cells, Cultured; Ciprofloxacin; Electric Impedance; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines | 2010 |
A comparative analysis of chromosomal aberrations in cultured human lymphocytes due to fluoroquinolone drugs at different expression periods.
Topics: Anti-Infective Agents; Cell Cycle; Cells, Cultured; Chromosome Aberrations; Ciprofloxacin; DNA Replication; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Humans; Lymphocytes; Ofloxacin | 2010 |
Synthesis and antitubercular evaluation of new fluoroquinolone derivatives coupled with carbohydrates.
Topics: Antitubercular Agents; Aza Compounds; Carbohydrates; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Quinolines | 2010 |
[Antimicrobial susceptibility patterns of Legionella isolates in the environment and in patients].
Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Legionella; Legionellosis; Microbial Sensitivity Tests; Naphthyridines | 2010 |
[Prevalence of Clostridium difficile in the gastrointestinal tract of hospitalized children under two years of age].
Topics: Aza Compounds; Ciprofloxacin; Clindamycin; Clostridioides difficile; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Female; Fluoroquinolones; Gastrointestinal Tract; Gatifloxacin; Genotype; Humans; Infant; Infant, Newborn; Male; Metronidazole; Moxifloxacin; Phenotype; Quinolines; Species Specificity; Vancomycin | 2010 |
Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.
Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Risk Factors; Staphylococcal Infections; Staphylococcus aureus | 2011 |
Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Topics: Anti-Bacterial Agents; Aza Compounds; Binding Sites; Canada; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2011 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Eye Infections, Fungal; Eye Infections, Parasitic; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2012 |
Induction of mycobacterial resistance to quinolone class antimicrobials.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines | 2012 |
Aluminium sensitized spectrofluorimetric determination of fluoroquinolones in milk samples coupled with salting-out assisted liquid-liquid ultrasonic extraction.
Topics: Acetonitriles; Aluminum; Ammonium Sulfate; Animals; Cattle; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Limit of Detection; Liquid-Liquid Extraction; Milk; Norfloxacin; Ofloxacin; Solutions; Spectrometry, Fluorescence; Temperature; Ultrasonics; Water | 2012 |
Effect of fluoroquinolone resistance selection on the fitness of three strains of Clostridium perfringens.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clostridium perfringens; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genetic Fitness; Microbial Sensitivity Tests; Microbial Viability; Mutation; Norfloxacin | 2013 |
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis | 2013 |
Spectrum of bacterial keratitis at a tertiary eye care centre in India.
Topics: Aza Compounds; Ciprofloxacin; Corneal Ulcer; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; India; Microbial Sensitivity Tests; Moxifloxacin; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus | 2013 |
Tracking the establishment of local endemic populations of an emergent enteric pathogen.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Chromosomes, Bacterial; Ciprofloxacin; Dysentery, Bacillary; Endemic Diseases; Evolution, Molecular; Fluoroquinolones; Gatifloxacin; Genetic Variation; Genome, Bacterial; Genomics; Geography; Humans; Infant; Molecular Sequence Data; Mutation Rate; Phylogeny; Sequence Analysis, DNA; Shigella sonnei; Vietnam | 2013 |
Effect of fluoroquinolones on mitochondrial function in pancreatic beta cells.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Ciprofloxacin; Flavin-Adenine Dinucleotide; Fluoroquinolones; Gatifloxacin; Glucose; Insulin-Secreting Cells; Mice; Mice, Knockout; Microscopy, Electron, Transmission; Mitochondria; Moxifloxacin; NADP; Quinolines; Sulfonylurea Receptors | 2014 |
Experimental and theoretical studies on the molecular properties of ciprofloxacin, norfloxacin, pefloxacin, sparfloxacin, and gatifloxacin in determining bioavailability.
Topics: Biological Availability; Buffers; Ciprofloxacin; Fluoroquinolones; Gastrointestinal Absorption; Gatifloxacin; Hydrogen-Ion Concentration; Models, Molecular; Molecular Conformation; Norfloxacin; Octanols; Pefloxacin; Phosphates; Solvents; Static Electricity; Thermodynamics | 2014 |
Molecularly imprinted polymers for the solid-phase extraction of four fluoroquilones from milk and lake water samples.
Topics: Animals; Ciprofloxacin; Enrofloxacin; Fluoroquinolones; Gatifloxacin; Lakes; Levofloxacin; Milk; Molecular Imprinting; Polymethyl Methacrylate; Solid Phase Extraction; Water Pollutants, Chemical | 2015 |
Patterns of Multi-Antibiotic-Resistant Escherichia Coli from Streams with No History of Antimicrobial Inputs.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Geologic Sediments; Microbial Sensitivity Tests; Rivers; Water Microbiology | 2016 |
In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gene Expression; Microbial Sensitivity Tests; Mutation; Quinolones; Sequence Analysis, DNA; Streptococcus pneumoniae; Structure-Activity Relationship | 2016 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary | 2016 |
Biophysical control of the growth of Agrobacterium tumefaciens using extremely low frequency electromagnetic waves at resonance frequency.
Topics: Agrobacterium tumefaciens; Amikacin; Anti-Bacterial Agents; Carbenicillin; Cefaclor; Chloramphenicol; Ciprofloxacin; DNA, Bacterial; Electromagnetic Radiation; Fluoroquinolones; Gatifloxacin; Gentamicins; Plant Tumors; Rifampin; Solanum lycopersicum | 2017 |
Effectiveness of treatment regimens for Typhoid fever in the nalidixic acid-resistant S. typhi (NARST) era in South India.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Hospitalization; Humans; India; Male; Microbial Sensitivity Tests; Nalidixic Acid; Recurrence; Salmonella typhi; Treatment Outcome; Typhoid Fever; Young Adult | 2018 |
The cardiovascular toxicity induced by high doses of gatifloxacin and ciprofloxacin in zebrafish.
Topics: Animals; Anti-Bacterial Agents; Cardiovascular Physiological Phenomena; Cardiovascular System; Ciprofloxacin; Down-Regulation; Gatifloxacin; Heart Rate; Humans; Models, Animal; Myocardial Contraction; Water Pollutants, Chemical; Zebrafish | 2019 |
Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Coinfection; Corynebacterium; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Retrospective Studies; Tertiary Care Centers; Vancomycin | 2022 |
Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Emergency Service, Hospital; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitals; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Retrospective Studies; Suicidal Ideation; Suicide; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |
Fluoroquinolone resistance in bacterial isolates from ocular infections: Trend in antibiotic susceptibility patterns between 2005-2020.
Topics: Anti-Bacterial Agents; Cefuroxime; Ciprofloxacin; Colistin; Eye Infections; Fluoroquinolones; Gatifloxacin; Humans; Longitudinal Studies; Moxifloxacin; Ofloxacin; Retrospective Studies | 2022 |